Browsing Tag
YK Bioventures
2 posts
Shenandoah Therapeutics appoints Steve Worland CEO as BCL6 cancer program nears IND studies
Shenandoah Therapeutics has appointed biotechnology veteran Steve Worland as chief executive officer, with co-founder Isabella Graef moving into the chief scientific officer role. The leadership change comes as the company's BCL6-targeting oncology program approaches IND-enabling studies, creating an important test of its transcriptional and epigenetic drug discovery platform.
Moonwalk Biosciences secures $70m Series B for adipose-targeted RNAi
Moonwalk Biosciences has secured $70 million to advance MW101 toward human testing, taking disclosed financing since launch to $127 million as the biotech pursues an adipose-targeted alternative to appetite-based obesity therapies.